Symbols / BRTX Stock $0.23 +3.19% BioRestorative Therapies, Inc.

Healthcare • Biotechnology • United States • NCM
BRTX (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Mr. Lance Alstodt
Exch · Country NCM · United States
Market Cap 5.86M
Enterprise Value 2.96M
Income -14.24M
Sales 359.70K
FCF (ttm) -6.20M
Book/sh 0.04
Cash/sh 0.12
Employees 13
Insider 10d —
IPO Dec 05, 2012
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E -0.44
PEG —
P/S 16.28
P/B 5.89
P/C —
EV/EBITDA -0.19
EV/Sales 8.23
Quick Ratio 0.80
Current Ratio 0.84
Debt/Eq 11.85
LT Debt/Eq —
EPS (ttm) -1.58
EPS next Y -0.52
EPS Growth —
Revenue Growth -54.70%
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-03-26
Earnings (prior) 2026-03-26
ROA -119.56%
ROE -3.20%
ROIC —
Gross Margin 93.37%
Oper. Margin -195.17%
Profit Margin 0.00%
Shs Outstand 25.48M
Shs Float 24.18M
Insider Own 12.13%
Instit Own 4.56%
Short Float 2.58%
Short Ratio 0.25
Short Interest 647.11K
52W High 2.04
vs 52W High -88.76%
52W Low 0.19
vs 52W Low 21.00%
Beta 0.27
Impl. Vol. —
Rel Volume 0.05
Avg Volume 9.80M
Volume 462.72K
Target (mean) $8.00
Tgt Median $8.00
Tgt Low $1.00
Tgt High $15.00
# Analysts 2
Recom None
Prev Close $0.22
Price $0.23
Change 3.19%
About

BioRestorative Therapies, Inc. develops therapeutic products and medical therapies using cell and tissue protocols primarily involving adult stem cells. The company develops programs related to the treatment of disc/spine disease and metabolic disorders. Its products pipeline comprises BRTX-100, a lead cell therapy candidate formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow, as well as used for the non-surgical treatment of painful lumbosacral disc disorders or as a complimentary therapeutic to a surgical procedure; and ThermoStem, a cell-based therapy candidate to target obesity and metabolic disorders using brown adipose derived stem cells to generate brown adipose tissue. The company also operates a commercial biocosmeceutical platform. In addition, it provides investigational curved needle device to deliver cells and/or other therapeutic products or material to the spine and discs, and other parts of the body. The company was formerly known as Stem Cell Assurance, Inc. and changed its name to BioRestorative Therapies, Inc. in August 2011. BioRestorative Therapies, Inc. is headquartered in Melville, New York.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$8.00
Mean price target
2. Current target
$0.23
Latest analyst target
3. DCF / Fair value
$-4.38
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$0.23
Low
$1.00
High
$15.00
Mean
$8.00

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2024-08-14 main Roth MKM Buy → Buy $18
2024-06-12 main Roth MKM Buy → Buy $15
2023-08-14 reit Roth MKM Buy → Buy $15
2022-12-07 init Roth Capital — → Buy $15
2022-09-28 init Maxim Group — → Buy $6
2021-12-01 init Roth Capital — → Buy $37
News
RSS: Latest BRTX news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2025-10-06 SILVA FRANCISCO Officer and Director — 11,719 $1.60 $18,750
2025-10-06 ALSTODT LANCE Chief Executive Officer — 15,625 $1.60 $25,000
2024-10-28 BROADRICK DALE Beneficial Owner of more than 10% of a Class of Security — 1,112 $1.58 $1,757
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
0.36
-10.30%
0.40
+175.03%
0.15
+21.70%
0.12
Operating Revenue
0.36
-10.30%
0.40
+175.03%
0.15
+21.70%
0.12
Cost Of Revenue
0.02
-15.06%
0.03
0.00
—
Reconciled Cost Of Revenue
0.02
-15.06%
0.03
0.00
—
Gross Profit
0.34
-9.94%
0.37
+155.78%
0.15
—
Operating Expense
15.98
+33.99%
11.93
-21.95%
15.28
-19.49%
18.98
Research And Development
10.09
+50.51%
6.71
+66.24%
4.03
+14.84%
3.51
Selling General And Administration
5.89
+12.78%
5.22
-53.93%
11.33
-27.27%
15.58
Selling And Marketing Expense
—
—
—
—
General And Administrative Expense
5.89
+12.78%
5.22
-53.93%
11.33
-27.27%
15.58
Other Gand A
5.89
+12.78%
5.22
-53.93%
11.33
-27.27%
15.58
Other Operating Expenses
—
—
-0.08
+24.60%
-0.11
Total Expenses
16.01
+33.88%
11.96
-21.77%
15.28
-19.49%
18.98
Operating Income
-15.65
-35.41%
-11.56
+23.66%
-15.14
+19.75%
-18.86
Total Operating Income As Reported
-15.65
-35.41%
-11.56
+24.08%
-15.22
+19.78%
-18.97
EBITDA
-15.44
-35.82%
-11.37
+24.08%
-14.97
+20.12%
-18.74
Normalized EBITDA
-16.56
-25.68%
-13.18
+30.55%
-18.97
+21.83%
-24.27
Reconciled Depreciation
0.21
+11.07%
0.19
+14.07%
0.17
+37.49%
0.12
EBIT
-15.65
-35.41%
-11.56
+23.66%
-15.14
+19.75%
-18.86
Total Unusual Items
1.12
-38.00%
1.81
-54.75%
4.00
-27.61%
5.52
Total Unusual Items Excluding Goodwill
1.12
-38.00%
1.81
-54.75%
4.00
-27.61%
5.52
Special Income Charges
—
—
0.00
-100.00%
0.25
Other Special Charges
—
—
—
-0.25
Restructuring And Mergern Acquisition
—
—
—
—
Net Income
-14.24
-58.61%
-8.98
+13.81%
-10.42
+21.21%
-13.22
Pretax Income
-14.24
-58.61%
-8.98
+13.81%
-10.42
+21.21%
-13.22
Net Non Operating Interest Income Expense
0.27
-56.79%
0.62
+11.55%
0.55
+4640.71%
0.01
Interest Expense Non Operating
—
—
—
—
Net Interest Income
0.27
-56.79%
0.62
+11.55%
0.55
+4640.71%
0.01
Interest Expense
—
—
—
—
Interest Income Non Operating
0.27
-56.79%
0.62
+11.55%
0.55
+4640.71%
0.01
Interest Income
0.27
-56.79%
0.62
+11.55%
0.55
+4640.71%
0.01
Other Income Expense
1.14
-41.88%
1.96
-52.98%
4.17
-25.97%
5.63
Other Non Operating Income Expenses
0.02
-88.43%
0.15
-11.09%
0.17
+58.43%
0.11
Gain On Sale Of Security
1.12
-38.00%
1.81
-54.75%
4.00
-24.18%
5.27
Tax Rate For Calcs
0.00
0.00
0.00
0.00
Tax Effect Of Unusual Items
0.00
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
-14.24
-58.61%
-8.98
+13.81%
-10.42
+21.21%
-13.22
Net Income From Continuing Operation Net Minority Interest
-14.24
-58.61%
-8.98
+13.81%
-10.42
+21.21%
-13.22
Net Income From Continuing And Discontinued Operation
-14.24
-58.61%
-8.98
+13.81%
-10.42
+21.21%
-13.22
Net Income Continuous Operations
-14.24
-58.61%
-8.98
+13.81%
-10.42
+21.21%
-13.22
Normalized Income
-15.36
-42.41%
-10.79
+25.16%
-14.42
+23.10%
-18.74
Net Income Common Stockholders
-14.24
-58.61%
-8.98
+13.81%
-10.42
+21.21%
-13.22
Diluted EPS
-1.58
-36.21%
-1.16
+53.04%
-2.47
+32.33%
-3.65
Basic EPS
-1.58
-36.21%
-1.16
+53.04%
-2.47
+32.33%
-3.65
Basic Average Shares
8.99
+15.83%
7.76
+84.05%
4.22
+16.60%
3.62
Diluted Average Shares
8.99
+15.83%
7.76
+84.05%
4.22
+16.60%
3.62
Diluted NI Availto Com Stockholders
-14.24
-58.61%
-8.98
+13.81%
-10.42
+21.21%
-13.22
Total Other Finance Cost
—
—
—
-0.01
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
4.08
-66.78%
12.28
-2.63%
12.61
-23.26%
16.43
Current Assets
3.14
-71.85%
11.14
-2.16%
11.39
-24.71%
15.13
Cash Cash Equivalents And Short Term Investments
2.95
-72.49%
10.73
-3.01%
11.07
-24.97%
14.75
Cash And Cash Equivalents
1.51
+175.82%
0.55
-38.05%
0.88
-48.40%
1.71
Cash Financial
—
—
—
—
Other Short Term Investments
1.44
-85.84%
10.18
+0.03%
10.18
-21.89%
13.04
Receivables
0.02
-91.77%
0.19
+876.17%
0.02
+20.63%
0.02
Accounts Receivable
0.02
-91.77%
0.19
+876.17%
0.02
+20.63%
0.02
Prepaid Assets
—
—
—
—
Other Current Assets
0.17
-24.54%
0.22
-26.87%
0.31
-15.93%
0.36
Total Non Current Assets
0.94
-16.98%
1.14
-7.01%
1.22
-6.51%
1.31
Net PPE
0.36
-1.15%
0.36
-28.49%
0.51
+0.94%
0.50
Gross PPE
1.59
+7.87%
1.47
-2.98%
1.52
+5.61%
1.44
Accumulated Depreciation
-1.23
-10.82%
-1.11
-9.81%
-1.01
-8.12%
-0.94
Buildings And Improvements
—
—
0.15
-37.36%
0.24
Machinery Furniture Equipment
0.28
+0.00%
0.28
+0.00%
0.28
+7.18%
0.26
Construction In Progress
0.06
0.00
—
—
Other Properties
0.91
+6.09%
0.85
-5.04%
0.90
+51.06%
0.59
Leases
0.34
+0.00%
0.34
+0.00%
0.34
+0.00%
0.34
Goodwill And Other Intangible Assets
0.53
-14.38%
0.62
-12.58%
0.71
-11.17%
0.80
Other Intangible Assets
0.53
-14.38%
0.62
-12.58%
0.71
-11.17%
0.80
Non Current Deferred Assets
0.05
-66.50%
0.15
0.00
—
Total Liabilities Net Minority Interest
3.72
-0.68%
3.75
+43.76%
2.61
-57.57%
6.14
Current Liabilities
3.72
-0.68%
3.75
+43.76%
2.61
-56.41%
5.98
Payables And Accrued Expenses
1.61
+207.52%
0.52
-41.90%
0.90
+199.39%
0.30
Payables
1.48
+191.92%
0.51
+168.52%
0.19
+10.82%
0.17
Accounts Payable
1.34
+177.70%
0.48
+155.07%
0.19
+10.82%
0.17
Other Payable
0.14
+461.40%
0.03
—
—
Current Accrued Expenses
0.13
+736.49%
0.01
-97.89%
0.71
+447.15%
0.13
Pensionand Other Post Retirement Benefit Plans Current
0.71
+1.35%
0.70
—
—
Current Debt And Capital Lease Obligation
—
—
0.16
+16.50%
0.14
Current Debt
—
—
—
—
Other Current Borrowings
—
—
—
—
Current Capital Lease Obligation
—
0.00
-100.00%
0.16
+16.50%
0.14
Other Current Liabilities
1.40
-44.49%
2.52
+63.27%
1.54
-72.14%
5.54
Total Non Current Liabilities Net Minority Interest
0.00
0.00
0.00
-100.00%
0.16
Long Term Debt And Capital Lease Obligation
—
—
—
0.16
Long Term Debt
—
—
—
—
Long Term Capital Lease Obligation
—
—
0.00
-100.00%
0.16
Stockholders Equity
0.36
-95.82%
8.53
-14.72%
10.00
-2.78%
10.29
Common Stock Equity
0.34
-95.98%
8.52
-14.74%
9.99
-2.77%
10.28
Capital Stock
0.01
+1.33%
0.01
+1.53%
0.01
-7.06%
0.02
Common Stock
0.00
+28.18%
0.00
+46.92%
0.00
+27.64%
0.00
Preferred Stock
0.01
+0.00%
0.01
+0.00%
0.01
-7.90%
0.02
Share Issued
8.88
+28.27%
6.92
+47.02%
4.71
+27.98%
3.68
Ordinary Shares Number
8.88
+28.27%
6.92
+47.02%
4.71
+27.98%
3.68
Additional Paid In Capital
170.26
+3.70%
164.20
+4.79%
156.69
+6.91%
146.56
Retained Earnings
-169.92
-9.15%
-155.68
-6.12%
-146.70
-7.64%
-136.28
Total Equity Gross Minority Interest
0.36
-95.82%
8.53
-14.72%
10.00
-2.78%
10.29
Total Capitalization
0.36
-95.82%
8.53
-14.72%
10.00
-2.78%
10.29
Working Capital
-0.59
-107.92%
7.40
-15.80%
8.78
-3.97%
9.15
Invested Capital
0.34
-95.98%
8.52
-14.74%
9.99
-2.77%
10.28
Total Debt
—
0.00
-100.00%
0.16
-46.19%
0.30
Capital Lease Obligations
—
0.00
-100.00%
0.16
-46.19%
0.30
Net Tangible Assets
-0.18
-102.24%
7.91
-14.89%
9.29
-2.07%
9.49
Tangible Book Value
-0.19
-102.43%
7.89
-14.91%
9.28
-2.06%
9.47
Preferred Shares Number
1.40
-9.40%
1.54
+10.37%
1.40
-7.90%
1.52
Preferred Stock Equity
0.01
+0.00%
0.01
+0.00%
0.01
-7.90%
0.02
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-10.79
-31.09%
-8.23
-27.99%
-6.43
-8.75%
-5.91
Cash Flow From Continuing Operating Activities
-10.79
-31.09%
-8.23
-27.99%
-6.43
-8.75%
-5.91
Net Income From Continuing Operations
-14.24
-58.61%
-8.98
+13.81%
-10.42
+21.21%
-13.22
Depreciation Amortization Depletion
0.21
+11.07%
0.19
+14.07%
0.17
+37.49%
0.12
Depreciation
0.12
+21.07%
0.10
+30.69%
0.08
+80.02%
0.04
Amortization Cash Flow
0.09
+0.00%
0.09
+0.00%
0.09
+14.57%
0.08
Depreciation And Amortization
0.21
+11.07%
0.19
+14.07%
0.17
+37.49%
0.12
Amortization Of Intangibles
0.09
+0.00%
0.09
+0.00%
0.09
+14.57%
0.08
Other Non Cash Items
—
0.15
+67.69%
0.09
+200.48%
-0.09
Stock Based Compensation
3.33
+18.24%
2.81
-63.86%
7.78
-38.29%
12.61
Operating Gains Losses
-1.39
+42.78%
-2.43
+46.73%
-4.57
+14.61%
-5.35
Gain Loss On Investment Securities
-1.39
+42.78%
-2.43
+46.73%
-4.57
+14.61%
-5.35
Unrealized Gain Loss On Investment Securities
—
—
—
-0.03
Change In Working Capital
1.31
+4470.12%
0.03
-94.44%
0.52
+3543.42%
0.01
Change In Receivables
0.17
+202.25%
-0.17
-5024.24%
-0.00
+70.00%
-0.01
Changes In Account Receivables
0.17
+202.25%
-0.17
-5024.24%
-0.00
+70.00%
-0.01
Change In Prepaid Assets
0.10
+202.97%
0.03
-41.94%
0.06
-20.86%
0.07
Change In Payables And Accrued Expense
1.03
+216.96%
0.33
-45.60%
0.60
+421.03%
0.12
Change In Accrued Expense
0.20
+495.39%
0.03
-94.36%
0.58
+11974.56%
-0.00
Change In Payable
0.84
+185.86%
0.29
+1488.58%
0.02
-84.60%
0.12
Change In Account Payable
0.84
+185.86%
0.29
+1488.58%
0.02
-84.60%
0.12
Change In Other Current Liabilities
0.00
+100.00%
-0.16
-16.50%
-0.14
+14.59%
-0.16
Investing Cash Flow
8.90
+1629.25%
0.51
-84.18%
3.25
+124.27%
-13.40
Cash Flow From Continuing Investing Activities
8.90
+1629.25%
0.51
-84.18%
3.25
+124.27%
-13.40
Net PPE Purchase And Sale
-0.12
-9.30%
-0.11
+37.92%
-0.17
+35.51%
-0.27
Purchase Of PPE
-0.12
-9.30%
-0.11
+37.92%
-0.17
+35.51%
-0.27
Capital Expenditure
-0.12
-9.30%
-0.11
+37.92%
-0.17
+61.15%
-0.44
Net Investment Purchase And Sale
9.01
+1352.11%
0.62
-81.87%
3.42
+126.41%
-12.96
Purchase Of Investment
-2.68
+87.17%
-20.89
-19.08%
-17.54
+21.87%
-22.45
Sale Of Investment
11.69
-45.64%
21.51
+2.60%
20.96
+120.86%
9.49
Net Intangibles Purchase And Sale
—
—
0.00
+100.00%
-0.17
Purchase Of Intangibles
—
—
0.00
+100.00%
-0.17
Financing Cash Flow
2.85
-61.31%
7.38
+214.18%
2.35
0.00
Cash Flow From Continuing Financing Activities
2.85
-61.31%
7.38
+214.18%
2.35
0.00
Net Issuance Payments Of Debt
—
—
—
0.00
Issuance Of Debt
—
—
—
0.00
Long Term Debt Issuance
—
—
—
0.00
Net Long Term Debt Issuance
—
—
—
0.00
Net Common Stock Issuance
3.10
0.00
-100.00%
2.35
0.00
Proceeds From Stock Option Exercised
0.04
-99.45%
7.53
0.00
—
Net Other Financing Charges
-0.28
-90.07%
-0.15
—
—
Changes In Cash
0.96
+386.28%
-0.34
+59.43%
-0.83
+95.71%
-19.31
Beginning Cash Position
0.55
-38.05%
0.88
-48.40%
1.71
-91.85%
21.03
End Cash Position
1.51
+175.82%
0.55
-38.05%
0.88
-48.40%
1.71
Free Cash Flow
-10.91
-30.81%
-8.34
-26.29%
-6.60
-3.90%
-6.35
Interest Paid Supplemental Data
0.00
0.00
0.00
0.00
Income Tax Paid Supplemental Data
0.00
0.00
0.00
0.00
Change In Interest Payable
—
—
—
—
Common Stock Issuance
3.10
0.00
-100.00%
2.35
0.00
Issuance Of Capital Stock
3.10
0.00
-100.00%
2.35
0.00
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category